BusinessbioAffinity Technologies Adds Four Scientists to Research & Commercialization TeamBy Nasdaq OMXJun 28, 2017, 6:00 PM UTC
BusinessbioAffinity Technologies Announces Award of European Union PatentBy Nasdaq OMXMay 3, 2017, 6:00 PM UTC
BusinessTESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast CancerBy Nasdaq OMXMar 27, 2017, 7:45 PM UTC
BusinessGenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH TestsBy Nasdaq OMXMar 7, 2017, 2:00 PM UTC
BusinessPeregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessCompanion Diagnostics Market worth 5.58 Billion USD by 2019; Transparency Market ResearchBy Nasdaq OMXSep 27, 2016, 12:04 PM UTC
BusinessbioAffinity Technologies Presents CyPath® Technology at International Lung Cancer ConferenceBy Nasdaq OMXApr 12, 2016, 1:00 PM UTC
